Affiris Ag

Ac Immune Sa

Advantage Therapeutics, Inc.

Accanis Biotech F&e Gmbh & Co Kg

Markus Mandler

Frank Mattner

Radmila Santic

Harald Weninger

Walter G Schmidt

Achim Schneeberger

Edith Kopinits

Arne Von Bonin

Christian Gieffers

Guenther Staffler

Wolfgang Zauner

Andreas Mairhofer

Andrea Dolischka

Günther Staffler

Christian Lahsnig

Oleksandr Otava

Walter Schmidt

A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVWPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107.

Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy

Disclosed is a method for the treatment of AD, wherein an immune stimulating pharmaceutical composition comprising an aluminium salt is administered to a patient having AD or having a risk to develop AD in an effective amount.

Treatment of Alzheimer's Disease (AD) with an aluminum salt

The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with &#x3b2;-amyloid deposition, preferably AD.

Treatment and prevention of alzheimer's disease (AD)

Treatment of alzheimer'S disease (AD) with an aluminum salt

A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVLPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107.

Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders

The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.

Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxide

Disclosed is a method for detecting aSyn-specific antibodies in a biological sample, comprising the following steps: &#x2014;contacting the sample with aSyn-comprising-aggregates and allowing the aSyn-specific antibodies to bind to the aSyn-comprising-aggregates, and &#x2014;detecting the aSyn-specific antibodies bound to the aSyn-comprising-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS).

Method for detecting aSyn-specific antibodies in a biological sample

The present invention relates to the use of at least one compound comprising the amino acid sequence 

The present invention relates to peptides or polypeptides for producing medicaments for preventing and/or treating synucleinopathies.

Means for treating synucleinopathies

The present invention relates to the use of mimotopes in the treatment of diseases associated with &#x3b2;-amyloid formation and/or aggregation (&#x3b2;-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to A&#x3b2;1-40/42, A&#x3b2;pE3-40/42, A&#x3b2;3-40/42 and A&#x3b2;11-40/42.

Compounds for treating beta-amyloidoses

The present invention relates to the use of mimotopes in the treatment of &#x3b2;-Amyloidoses including but not limited to Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to non truncated A&#x3b2;1-40/42, and N-terminally truncated forms A&#x3b2;pE3-40/42, A&#x3b2;3-40/42, A&#x3b2;11-40/42, A&#x3b2;pE11-40/42 and A&#x3b2;14-40/42 without interfering with physiological functions of APP signalling.

Growing community of inventors

Vienna, Austria

Markus Mandler